The promise of Cubist Pharmaceuticals is based on both a current product, CUBICIN® (daptomycin for injection), which represents the most successful IV antibiotic launch, in dollar terms, in U.S. history, as well as on internal discovery and external sourcing of acute care drug candidates.
Cubist is continuing research to help optimize knowledge about the utility and advantages of CUBICIN in the infectious disease armamentarium. CUBICIN development includes a Phase 2 high dose short duration (10 mg/kg for 4 days) cSSSI study and a Phase 2 comparative dose (6 and 8 mg/kg) study in prosthetic joint infections. Cubist believes CUBICIN will continue growing (to greater than $750 Million annually in the U.S. alone) with its current labeled indications and has not yet made decisions on the appropriateness of additional registration (Phase 3) studies.
The company has a growing early stage pipeline of programs which can leverage Cubist's scientific, clinical and regulatory expertise as well as its proven acute care commercial organization. The company's intent is to continue to build this pipeline using internal discovery, research collaborations, in-licensing and acquisition to maximize the opportunity for a flow of IND filings in the years ahead, thus enabling continued revenue growth beyond CUBICIN, which has patent protection in the U.S. through 2019. Our pre-clinical programs include research focused on therapy for: clostridium difficile-associated diarrhea or CDAD; multi drug resistant Gram-negative infections; Hepatitis C Virus (HCV) infections.
 Learn more about CUBICIN |
Learn more about CDAD |
| Learn more about Ecallantide |
Learn more about Hepatitis C |
| Discovery |